Drug, bio-affecting and body treating compositions inventions 10/09

20090246124 - High affinity vegf-receptor antagonists: A cell-based screen is reported can be used to identify specific receptor-binding compounds in a combinatorial library of peptoids (N-alkylglycine oligomers) displayed on beads. This strategy was applied to the isolation of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)-binding peptoids, which were optimized to create lead compounds with high affinity... Agent: Fulbright & Jaworski L.l.p.

20090246123 - Pharmaceutical gels and methods for delivering therapeutic agents to a site beneath the skin: Pharmaceutical gels and methods for delivering a therapeutic agent to a target tissue site beneath the skin of a patient are provided, the gel being capable of adhering to the target tissue site and comprising one or more biodegradable depots containing an effective amount of the therapeutic agent. In various... Agent: Medtronic Attn: Noreen Johnson - Ip Legal Department

20090246125 - Magnetic resonance contrast media: An image enhancing agent of a form comprising an effective quantity of an image enhancing material chemically or physically bound to or encapsulated within a support comprising, preferentially, an exine coating of spores of various plants or fungi, optionally with further excipients.... Agent: Weaver Austin Villeneuve & Sampson LLP

20090246126 - Thulium-based capsule and devices for use in high dose rate brachytherapy: A capsule for high dose rate brachytherapy, wherein the capsule comprises within its interior space thulium-170, and further comprises at least one layer of a radiation emission modifying metal (e.g., gold), wherein said layer is provided either internally within the capsule or on the outer surface thereof.... Agent: Nixon & Vanderhye, Pc

20090246127 - Targeting agents for molecular imaging: This invention discloses a method of synthesizing targeting contrast agents for molecular imaging and targeting diagnosis and therapy, targeting contrast agents and targeting therapeutic agents and the use thereof.... Agent: Philips Intellectual Property & Standards

20090246128 - Composition and method for detection of pre-metastatic sites: A radio-immunoconjugate for diagnosis and treatment of cancer or metastasis and development of metastasis inhibitory formulations using the same is provided. Also, a radio-immunoconjugate is used as a material indicating a metastatic cancer that has antibody marked with any lanthanum radionuclide and/or gamma, beta or alpha ray emitting radioisotopes targeting... Agent: Bardmesser Law Group, P.c.

20090246129 - Compositions and methods for the diagnosis and treatment of tumor: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090246130 - Methods and compositions for f-18 labeling of proteins, peptides and other molecules: The present application discloses compositions and methods of synthesis and use of 18F or 19F labeled molecules of use in PET or MRI imaging. The labeled molecules may be peptides or proteins, although other types of molecules may be labeled. Preferably, the 18F or 19F is conjugated to a targeting... Agent: Immunomedics, Inc.

20090246131 - Production and use of novel peptide-based agents for use with bi-specific antibodies: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodies have been prepared. In preferred... Agent: Immunomedics, Inc.

20090246133 - Methods and compositions related to internalizing rgd peptides: Disclosed are compositions and methods useful for targeting tissue undergoing angiogenesis or to cells or tissue expressing αv integrins. The compositions and methods are based on peptide sequences that selectively bind to and home to tissue undergoing angiogenesis or to cells or tissue expressing αv integrins in animals. The disclosed... Agent: Patent Correspondence Arnall Golden Gregory LLP

20090246132 - Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof: The invention relates to murine monoclonal antibodies (MAbs), A, B, C and D, which are directed against tumor-associated antigens. The nearly complete nucleotide sequences of the V genes of these MAbs are described, so that the relevant variable domains can be put together to give chimeric MAbs, or “humanized” MAbs... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090246134 - Compositions and methods for modulating gated ion channels: The present invention is directed toward radiolabelled ASIC imaging agents, as well as metabolites of ASIC antagonists. These compounds are useful for the diagnosis and treatment of diseases and disorders related to the activity of gated ion channels.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090246135 - Diagnostic agent: A diagnostic agent for being sprinkled to the inner wall of a gastrointestine in endoscopic observation, comprising an acidic aqueous solution of pH 1 to 5 containing a colorant and also containing at least one acid selected from the group consisting of a carboxylic acid, hydrochloric acid, sulfuric acid and... Agent: Buchanan, Ingersoll & Rooney Pc

20090246136 - Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration: The present invention relates to the identification of miRNAs that are involved in the process of neuromuscular synaptic maintenance and regeneration following injury or disease. Modulation of these miRNAs is proposed as treatment for spinal cord injury and neurodegenerative disease.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090246137 - Pyridyl derivatives as cftr modulators: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.... Agent: Vertex Pharmaceuticals Inc.

20090246139 - Efficient methods to isolate effectors of proteins involved in olfactory or chemosensory pathways and efficient methods to use these effectors to alter organism olfaction, chemosensation, or behavior: This invention provides methods and compositions for identifying effectors, binding partners, or other molecules that interact with the proteins involved in the chemosensory pathway; examples of proteins involved in the olfactory pathway include odorant binding proteins (OBPs), sensory appendage proteins (SAPs), orthologs of the Drosophila melanogaster Takeout protein (TOLs), odorant... Agent: David R Preston & Associates Apc

20090246138 - Method of imaging metabolic function: A contrast imaging method e.g. of the T2* weighted “BOLD” type is adapted by use together with an oxygen challenge to provide imaging for the assessment of the metabolic responses of tissue over a period of time the method utilizing three components, oxygen, deoxyhaemoglobin, and oxyhaemoglobin together with time, to... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090246140 - Methods for identifying and targeting autonomic brain regions: Disclosed herein are methods for identifying and targeting autonomic and autonomic-related brain regions. In one embodiment, a method of identifying a brain region in a patient comprises administering to the patient a targeting agent that activates or inhibits a brain region and imaging the brain region.... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20090246143 - Non-radioactive traceable metal isotope-enriched nanoparticles and method of their use for determining biodistribution: Composition of non-radioactive traceable metal isotope-enriched nanoparticles, and methods of their use for determining in-vivo biodistribution are provided. The methods comprise the steps of: (a) introducing the nanoparticles into the biological material, wherein the nanoparticles comprise at least one inorganic core, and the inorganic core comprises at least two metal... Agent: General Electric Company Global Research

20090246144 - System and method for indirectly measuring calcium ion efflux: A system and method for indirectly measuring calcium ion efflux from a cell of a subject by using manganese ions as a surrogate marker for calcium is disclosed. Manganese ion efflux is measured with a MEMRI T1-mapping method while the calcium-sodium exchanger is inhibited.... Agent: Gardner Groff Greenwald & Villanueva. Pc

20090246145 - Imaging correlates of neurogenesis with mri: This invention provides a method for treating a mammalian subject afflicted with a disorder associated with reduced neurogenesis in the subject's hippocampal dentate gyrus which comprises administering to the subject a therapeutically effective amount of a compound which increases cerebral blood volume in the subject's hippocampal dentate gyrus by a... Agent: Cooper & Dunham, LLP

20090246141 - Higher fatty acid triester and amide derivative having diethylenetriamine-type metal chelate structure: A compound having superior solubility and suitable for a liposome contrast medium selective for a lesion such as vascular diseases is provided which is represented by the following general formula (I) wherein R1 to R3 represent an alkyl group or alkenyl group; X1 and X2 represent a single bond, —O—,... Agent: Sughrue Mion, Pllc

20090246142 - Triggered self-assembly of nanoparticles in vivo: The present invention provides triggered self-assembly nanosystems. Such nanosystems comprise a population of triggered self-assembly conjugates, each conjugate comprising one or more monomeric units and one or more complementary binding moieties. In some embodiments, inventive nanosystems and conjugates can be used to treat and/or diagnose a disease, disorder, and/or condition.... Agent: Choate, Hall & Stewart LLP

20090246146 - Halides in the treatment of pathogenic infection: The present invention relates to the use of halides and halide salts for the treatment of microbial infections, including those caused by bacteria, fungi and viruses. The present invention takes advantage of endogenous immune function and augments this system using a non-toxic and inexpensive reagent that can be delivered to... Agent: Fulbright & Jaworski L.l.p.

20090246147 - Delivery of antipsychotics through an inhalation route: The present invention relates to the delivery of antipsychotics through an inhalation route. Specifically, it relates to aerosols containing antipsychotics that are used in inhalation therapy. In a method aspect of the present invention, an antipsychotic is delivered to a patient through an inhalation route. The method comprises: a) heating... Agent: Swanson & Bratschun, L.l.c

20090246149 - Medicinal aerosol formulations: Use of particulate bulking agents having an extremely small mass median diameter of less than one micron, preferably less than 300 nm, in pharmaceutical aerosol formulations comprising a suspension of drug particles in a propellant. Examples of bulking agents include ascorbic acid, saccharides, polysaccharides, amino acids, organic and inorganic salts,... Agent: 3m Innovative Properties Company

20090246148 - Medicinal aerosols and methods of delivery thereof: e

20090246150 - Antimicrobial composition: The present invention relates to novel antimicrobial composition comprising a peptide which can be obtained from the milk protein casein or chemically synthesised or produced by recombinant DNA technology and a divalent cation.... Agent: Bozicevic, Field & Francis LLP

20090246151 - Processes of making oral compositions containing gel networks: The present invention is directed towards a process for making oral compositions comprising gel networks. The gel networks are formed from a fatty amphiphile dispersion and swelling surfactant. The fatty amphiphile dispersion comprises one or more fatty amphiphiles, one or more dispersing surfactants, and one or more solvents. A gel... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090246155 - Compositions and methods for personal care: Systems and methods for delivering personal care materials. Crystalline polymeric systems, referred to as CYC carriers, are associated with the cosmetic materials, through chemical bonding or through physical association. The crystallinity of the CYC carriers results from the presence of crystallizable side chains, for example long chain n-alkyl moieties, which... Agent: Bell & Associates

20090246153 - Cosmetic compositions for the inhibition of reactive oxygen species: A composition and method having anti-aging properties is provided. The composition comprises an arNOX inhibitory agent present in a natural plant extract and is useful topically as a cosmetic. The symptoms of aging including lines, wrinkles, hyperpigmentation, dehydration, loss of elasticity, angioma, dryness, itching, telangietasias, actinic purpura, seborrheic keratoses and... Agent: Dorsey & Whitney LLP Intellectual Property Department

20090246152 - Naractin compositions for the inhibition of reactive oxygen species: The invention relates to agents for sequestering serum aging factors, and methods for using the same. More particularly, the invention relates to agents termed herein “Naractin” to denote any one of several naturally-occurring arNOX inhibitors either present in N. tazetta powder or capable of augmenting N. tazetta powder to an... Agent: Dorsey & Whitney LLP Intellectual Property Department

20090246154 - Use of aminophenylbenzotriazole derivatives for protecting human and animal skin and hair from the harmful effects of uv radiation and cosmetic compositions thereof: e

20090246156 - Anti-acne sunscreen composition: The present invention is directed to compositions for anti-acne sunscreen. The sunscreen composition has the unique ability to treat and prevent acne in addition to screen both UVA and UVB radiation. In particular, the sunscreen composition includes a sunscreen base, at least one UVA deactivator, at least one UVB deactivator,... Agent: Husch Blackwell Sanders LLP

20090246157 - Method of quenching electronic excitation of chromophore-containing organic molecules in photoactive compositions: wherein A and B are the same or different and are selected from the group consisting of oxygen, amino and sulfur; R1 and R3 are the same or different and are selected from the group consisting of C1-C30 alkyl, C2-C30 alkylene, C2-C30 alkyne, C3-C8 cycloalkyl, C1-C30 substituted alkylene, C2-C30 substituted... Agent: Marshall, Gerstein & Borun LLP

20090246158 - Antioxidants: The present invention relates to the use of compounds of the formula (I) where R stands for [lacuna] with radicals defined in the description, as antioxidants, to corresponding novel compounds and compositions, and to corresponding processes for the preparation of compounds and compositions.... Agent: Millen, White, Zelano & Branigan, P.c.

20090246159 - Composition and process for treating keratinous substrates with at least two immiscible cosmetic compositions: A process for treating a keratinous substrate involving: (a) providing at least a first composition having a continuous phase whose major ingredient has a solubility parameter corresponding to δ; (b) providing at least a second composition having a continuous phase whose major ingredient has a solubility parameter corresponding to δ′;... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090246160 - Oxidizing aqueous dispersion for treating keratin fibers comprising at least one nonionic amphiphilic hydrophobic compound: The subject of the present disclosure is a composition for treating keratin fibers comprising, in a cosmetically acceptable medium, at least one oxidizing agent; at least one nonionic amphiphilic hydrophobic compound which is solid at ambient temperature; and, optionally, at least one hydrophilic surfactant; wherein the weight ratio of the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090246163 - Anti-static skin products and method: An aqueous or non-aqueous preparation comprising cationic agents to neutralize a negative charge thereby relieving tension in the skin and preventing moisture from escaping. It relieves static-tension in the skin thereby reducing the distance between the pores. The difference between the Present Invention and other water based skin conditioners is... Agent: Stanley H. Kremen

20090246161 - Cationic capped dimer acid polyesters in personal care applications: The present invention is directed to a series of cationic polyester compounds made from the reaction of (a) a difunctional hydroxy compound, specifically polyoxyalkylene glycols, (b) a difunctional carboxylic acid, specifically dimer acid and hydrogenated dimer acid, and (c) a capping cationic, hydroxyl containing compound which only contains one hydroxyl... Agent: Anthony J. O'lenick, Jr.

20090246164 - Tissue adhesion: A method of adhering biological tissue that includes applying a bio-degradable adhesive to the tissue. The adhesive includes a moisture-curable, isocyanate-functional component prepared by reacting (a) a multi-functional isocyanate component and (b) a multi-functional active hydrogen component that includes at least 30% by weight, based upon the total weight of... Agent: Bartony & Hare, LLP

20090246165 - Disinfectant with quarternary ammonium polymer and copolymers: An alcohol-soluble, water-insoluble, disinfectant composition and a method of using the same for disinfecting and for providing a prolonged antimicrobial property to a variety of surfaces, including skin. The composition comprises an antimicrobial polymer that is capable of imparting an antimicrobial property to a surface without the use of a... Agent: Elman Technology Law, P.c.

20090246166 - Pearl like polyvinyl alcohol particles, production process thereof and temporary vascular embolic agent: The embodiments provide a temporary vascular embolic agent temporarily blocking the blood vessel in vivo, having appropriate dissolution speed suitable for use in the blood vessel in which blood flow is fast and being more superior in the passing property of a catheter and the controllability of embolization time than... Agent: Rahman Llc

20090246167 - Stimuli-responsive systems for controlled drug delivery: A method of delivering a therapeutic agent by providing a cross-linked polymer encapsulating the therapeutic agent to a site in a patient. The degradation rate of the cross-linked polymer is correlated with a local concentration of an indicator, and the therapeutic agent is released as the cross-linked polymer degrades.... Agent: Choate, Hall & Stewart LLP

20090246162 - Treatment of chronic progressive heart failure: The invention provides a method for treating or preventing heart failure in a subject, which includes administering to the subject in need thereof a therapeutically effective amount of a Poloxamer (e.g., Poloxamer 188).... Agent: Honigman Miller Schwartz & Cohn LLP

20090246168 - Antitumoral treatments: The present invention relates to combinations of aplidine or aplidine analogues with other antitumoral agents, and the use of these combinations in the treatment of cancer, in particular in the treatment of lung cancer, breast cancer, colon cancer, prostate cancer, renal cancer, melanoma, multiple myeloma, leukemia and lymphoma.... Agent: King & Spalding

20090246169 - Indolopyridines as eg5 kinesin modulators: Compounds of a certain formula I, in which R1, R2, R3, R4, R5 and R6 have the meanings indicated in the description, are effective compounds with anti-proliferative and/or apoptosis inducing activity.... Agent: Millen, White, Zelano & Branigan, P.c.

20090246170 - Therapeutic agent for alzheimer's disease: The present invention provides novel therapeutic methods and agents for treating Alzheimer's disease. Specifically, the present invention relates to anti-inflammatory cytokines, anti-inflammatory cytokine genes, negative-strand RNA viral vectors carrying an anti-inflammatory cytokine gene, which are used for treating Alzheimer's disease or developing therapeutic agents for Alzheimer's disease. The present invention... Agent: Clark & Elbing LLP

20090246171 - Automatic system for dose control in treating hepatitis c using infusion pumps: According to one embodiment, a method of controlling a plurality of treatment dosages for Hepatitis C includes: setting a first dosage level to cause a viral load of a subject user to reduce at a rate over time; determining, after setting the first dosage level, if the rate of the... Agent: Foley & Lardner

20090246172 - Compositions comprising epothilones and their use for the treatment of carcinoid syndrome: c

20090246173 - Treatment with anti-vegf antibodies: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.... Agent: Genentech, Inc.

20090246174 - Treatment for cutaneous t cell lymphoma: The present invention provides method for treating a patient with cutaneous T cell lymphoma (CTCL). Generally, the methods include administering to the patient an IRM compound in an amount effective to ameliorate at least one symptom or clinical sign of CTCL. In some embodiments, the methods also include administering to... Agent: 3m Innovative Properties Company

20090246176 - Method for treating diabetes mellitus, obesity, chronic fatigue, aging, and other medical conditions by utilizing modified virus virions to insert messenger ribonucleic acid molecules into cells: The common link between diabetes mellitus, obesity, chronic fatigue and even aging may be related to deficiencies involving a body's metabolism of glucose and the ability to optimally conduct the necessary biologic processes of aerobic respiration. Utilizing a modified form of virus to deliver to cells in the body the... Agent: Lane B. Scheiber

20090246175 - Therapeutic use of scin, a staphylococcal complement inhibitor in inflammatory diseases: The present invention relates to the use of the staphylococcal complement inhibitor (SCIN) or a homologue thereof, or a derivative or a fragment of SCIN or the SCIN homologue for the preparation of a medicament for intervening with C3 and C5 convertases. The medicament is in particular intended for inhibiting... Agent: Bozicevic, Field & Francis LLP

20090246183 - Enos mutations useful for gene therapy and therapeutic screening: The present invention relates to new NOS variants or mutants which contain structural alterations in the site of Akt dependent phosphorylation. The altered NOS proteins or peptides, especially the human eNOS proteins or peptides, Akt proteins or polypeptides and their encoding nucleic acid molecules are useful as gene therapy agents... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090246182 - Method for culturing cells derived from the adipose tissue and uses thereof: The invention concerns a method for culturing cells derived from the adipose tissue and in particular the stromal vascular fraction (SVF) to induce formation of cardiomyocytes, the use of the cells obtained by said culture method to reconstitute an ischemized cardiac zone, in particular following an infarction, as well as... Agent: Alston & Bird LLP

20090246177 - Megasphaera elsdenii strain and its uses: This invention relates to a novel strain of Megasphaera elsdenii and its uses. This invention further relates to preparations and methods incorporating such strain. This invention also relates to feedstuffs for ruminants and a preparation and method for the prevention and treatment of lactic acidosis in ruminants. This invention even... Agent: Mirick, O'connell, Demallie & Lougee, LLP

20090246184 - Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same: The disclosure relates to a solid glass matrix of polysaccharide, saccharides and polyols as delivery vehicle for preservation and post gastric administration of a probiotic. The delivery vehicle is capable of releasing the probiotic at their site of action. The present invention further includes methods of making and using the... Agent: Moore & Van Allen Pllc

20090246178 - Cd56 positive human adult pancreatic endocrine progenitor cells: The invention relates to the discovery of a selective cell surface marker that permits the selection of a unique subset of pancreatic stems cells having a high propensity to differentiate into insulin producing cells or into insulin producing cell aggregates.... Agent: Morrison & Foerster LLP

20090246180 - Hypoxia inducing factors and uses thereof for inducing angiogenesis and improving muscular functions: This invention provides HIF-3α nucleic acid and sequences. Also provided are methods for using HIF-3α nucleic acids, proteins, fragments, antibodies, probes, and cells, to characterize HIF-3α, modulate HIF-3α cellular levels, induce angiogenesis, improve muscular function, and treat coronary and cardiac diseases in mammals.... Agent: Myers Bigel Sibley & Sajovec

20090246179 - Method of treating myocardial injury: A method of treating a myocardial injury of a subject includes administering a population of at least one of mesenchymal stem cells (MSCs), multipotent adult progenitor cells (MAPCs), embryonic stem cells (ESCs), induced pluripotent stem cells (iPSs), which have down-regulated expression of disabled-2 (Dab2), to the subject.... Agent: Tarolli, Sundheim, Covell & Tummino L.l.p.

20090246181 - Therapeutic composition for atopic dermatitis: A novel type of therapeutic agent, human mesenchymal stem cells, and a composition containing the same for the treatment of atopic dermatitis is disclosed. A method for the treatment of atopic dermatitis in patient is also disclosed.... Agent: Millen, White, Zelano & Branigan, P.c.

20090246186 - Agent for improving nervous system cell functions: An agent for improving a neural cell function containing reduced coenzyme Q as an active ingredient, more specifically, an agent for activating neural cells and an agent for protecting neural cells, is useful, and can be used for the improvement or prophylaxis of central neurological diseases or neuropathy symptoms derived... Agent: Sughrue Mion, Pllc

20090246185 - Cardiac dysfunction-ameliorating agent or cardiac function-maintaining agent: An object of the present invention is to provide a highly safe oral composition superior in a cardiac dysfunction-ameliorating or cardiac function-maintaining action. The present inventors have conducted intensive studies in an attempt to solve the aforementioned problems and found that use of, particularly, reduced coenzyme Q10 from among highly... Agent: Sughrue Mion, Pllc

20090246187 - Process for concentration of a polypeptide: The present invention comprises a method of concentrating a composition comprising a polypeptide of interest and the use of such a concentrated composition for the treatment of diseases in mammals, in particular by subcutaneous injection.... Agent: Foley And Lardner LLP Suite 500

20090246188 - Method for production of a bioengineered form of tissue plasminogen activator: The present invention relates to the recombinant method used for the production of soluble form of human tissue plasminogen activator variant. In this variant the threonine at position 103 of the endogenous tissue plasminogen activator is replaced by an asparagine leading to a new glycosylation site. At position 117 of... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090246192 - 1d05 pcsk9 antagonists: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host... Agent: Merck And Co., Inc

20090246190 - Anti-vegf antibody: An antibody is provided. In certain cases, the antibody comprises: a) a heavy chain variable domain that comprises CDR regions that are substantially identical to the heavy chain CDR regions of a selected antibody and b) a light chain variable domain that comprises CDR regions that are substantially identical to... Agent: Bozicevic, Field & Francis LLP

20090246193 - Inactivating organisms using carbon dioxide at or near its supercritical pressure and temperature conditions: Whole organisms are inactivated by at least a factor of 106 using carbon dioxide at or near its supercritical pressure and temperature conditions.... Agent: Welsh & Flaxman Llc

20090246189 - Methods for promoting neurite outgrowth and survival of dopaminergic neurons: The present invention relates generally to methods for promoting regeneration, outgrowth and survival of dopaminergic neurons comprising contacting said dopaminergic neurons with an effective amount of a composition comprising an Sp35 antagonist. Additionally, the invention is related generally to methods of treating various diseases, disorders or injuries associated with dopaminergic... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20090246191 - Preparation of purified covalently cross-linked abeta oligomers and uses thereof: The present invention provides a method of purifying cross-linked oligomers. The purified cross-linked oligomers are useful as immunogen for generating and isolating cross-linked oligomer reactive antibodies. The cross-linked oligomer reactive antibodies are useful for detecting amyloid deposition and for diagnosing and treating diseases and conditions associated with amyloid deposition.... Agent: Morgan Lewis & Bockius LLP

20090246195 - Anti-cd19 antibody therapy for transplantation: The invention relates to immunotherapeutic compositions and methods for the treatment and prevention of GVHD, humoral rejection, and post-transplantation lymphoproliferative disorder in human subjects using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or... Agent: Ropes & Gray LLP

20090246197 - Combination therapy of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc): The present invention is also directed to a method for the treatment of a CD20 expressing cancer, comprising administering to a patient in need of such treatment (i) an effective first amount of a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity; and (ii) an effective second amount... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090246196 - Combined targeted therapy for the treatment of proliferative disease: A method of treating an individual comprising: evaluating the disease state of said individual through quantitative and/or qualitative assays; administering in amounts sufficient to treat said disease at least three agents wherein at least one agent is an inhibitor of the human epidermal receptor pathway, at least one agent is... Agent: Conley Rose, P.c. David A. Rose

20090246194 - Erythropoietin analog-igg fusion proteins: Erythropoietin analog-human IgG fusion protein (EPOa-IgG) fusion protein and methods of making and using the fusion protein.... Agent: Gtc Biotherapeutics, Inc. C/o Wolf, Greenfield & Sacks, P.c.

20090246198 - Mapk/erk kinase inhibitors and methods of use thereof: y

20090246199 - Therapeutic methods for inhibiting tumor growth with dll4 antagonists: Disclosed is a therapeutic method for inhibiting development or growth of tumors that are resistant to the blockade of delta-like ligand 4 (Dll4), or vascular endothelial growth factor (VEGF), or to other therapeutic agents, by administering the combination of Dll4 antagonist and VEGF antagonist. The combined administration of these two... Agent: Regeneron Pharmaceuticals, Inc

20090246200 - Anthrax carbohydrates, synthesis and uses thereof: The present invention presents the isolation, characterization and synthesis of oligosaccharides of Bacillus anthracis. Also presented are antibodies that bind to such saccharide moieties and various methods of use for such saccharide moieties and antibodies.... Agent: Mueting, Raasch & Gebhardt, P.a.

20090246202 - Human endokine alpha and methods of use: The present invention concerns a novel member of the tumor necrosis factor (TNF) family of cytokines. In particular, isolated nucleic acid molecules are provided encoding the endokine alpha protein. Endokine alpha polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090246201 - Substances: The present invention provides a homologue to heparanase which is present in three splice variants.... Agent: Klauber & Jackson

20090246203 - Method for immunoadsorption by means of autoanitgens: The invention relates to a novel method for immunoadsorption therapy of human autoimmune diseases by means of immobilized or fixed autoantigens.... Agent: Connolly Bove Lodge & Hutz, LLP

20090246204 - Use of a cd28 binding substance for making a pharmaceutical composition: The invention relates to the use of a CD28-specific superagonistic monoclonal antibody (mAb) or of a mimicry compound hereto for making a pharmaceutical composition for the induction and/or multiplication of regulatory T cells.... Agent: Mayer & Williams Pc

20090246205 - Inhibition of macrophage-stimulating protein receptor (ron): The present invention relates to methods for treatment of tumors and other diseases in a mammal comprising administration of antibodies specific for Macrophage-Stimulating Protein Receptor (“MSP-R” or “RON”). The present invention further provides for compositions comprising antibodies or antibody fragments specific for RON, including human antibodies, that inhibit RON activation.... Agent: Eli Lilly & Company

20090246206 - Bispecific binding agents for modulating biological activity: Methods for improving the specific binding ability of bispecific binding compositions are described. The bispecific binding compositions are able to target cells by a high affinity targeting domain to a target cell surface marker and a low affinity binding domain that binds specifically to a second cell surface marker, wherein... Agent: Townsend And Townsend And Crew, LLP

20090246207 - Calf biologic anti-scour supplement (cbas): A composition for prevention digestive infection in a ruminant infant is disclosed. The composition consists of: a predetermined amount of yolk immunoglobulin (IgY) for a target bacteria; a predetermined amount of a plurality of hormones and a predetermined amount of a plurality of proteins, wherein said plurality of hormones comprises... Agent: Barry Choobin

20090246209 - Gnrh analogues for treatment of urinary incontinence: The use of at least one GnRH analogue for the preparation of a medicament for the prevention and/or treatment of side effects of ovarectomy or symptoms associated with reproductive senescence in female mammals, in particular urinary incontinence, hot flushes, and skin/hair changes are disclosed.... Agent: Joyce Von Natzmer Pequignot + Myers Llc

20090246210 - Il-1beta binding antibodies and binding fragments thereof: An IL-1β binding antibody or IL-1β binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 26 and SEQ ID NO: 11, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease. IL-1β binding antibodies or IL-1β... Agent: K&l Gates LLP

20090246208 - Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis: Methods for preventing and treating osteolysis, cancer metastasis and bone loss associated with cancer metastasis by administering an M-CSF-antagonist in combination with a therapeutic agent to a subject are provided.... Agent: Marshall, Gerstein & Borun LLP

20090246211 - Molecular constructs suitable for targeted conjugates: t

20090246212 - Development of method for screening for drug capable of improving production of regulatory t cells and method for producing regulatory t cells using immunosuppressive macrolide antibiotic: The present invention also provides a method of producing regulatory T cells, comprising culturing CD4+ T cells having a naïve phenotype in the presence of a rapamycin compound to obtain regulatory T cells. The regulatory T cell produced by the method can be used as an immunomodulator for the prophylaxis... Agent: Leydig Voit & Mayer, Ltd

20090246214 - Fusion proteins containing recombinant cytotoxic rnases: Recombinant immunotoxins containing a cytotoxic RNAse fused to an antibody or antibody fragment may be produced in mammalian cell culture. Surprisingly, immunotoxins containing a cytotoxic RNAse fused to the N-terminus of one antibody variable domain can be prepared and retain the ability to specifically bind antigen. The immunotoxins may be... Agent: Rossi, Kimms & Mcdowell LLP.

20090246213 - Vaccine comprising a polynucleotide encoding an antigen recognized by a cd4+ helper t-cell and a polynucleotide encoding a tumor specific or associated antigen recognized by a cd8+ ctl: The present invention relates to a DNA vaccine for developing tumor-specific immunity. Specifically, the invention relates to a DNA vaccine comprising antigens recognized by CD4+ helper T cells and CD8+ cytotoxic T cells, respectively. Preferably, the antigen recognized by CD4+ helper T cells is a molecule identified by the SEREX... Agent: Townsend And Townsend And Crew, LLP

20090246215 - Amyloid beta1-6 antigen arrays: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an Aβ1-6 peptide-VLP-composition. More specifically, the invention provides a composition comprising a virus-like particle and at least... Agent: Volpe And Koenig, P.c.

20090246216 - Novel attenuated poliovirus: A novel and stable attenuated poliovirus, which replicates in neuroblastoma cells, is produced by engineering an indigenous replication element (cre), into the 5′ non-translated genomic region and inactivating the native cre element located in the coding region of 2C (mono-crePV). The stably attenuated poliovirus replicates in a neuroblastoma model (Neuro-2aCD155... Agent: Kenyon & Kenyon LLP

20090246217 - Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity: In one aspect, the present invention provides isolated novel peptides that can be used to modulate innate immunity in a subject, and/or for the treatment of an immune-related disorder, including treating and preventing infection by modulating innate immunity. Also provided are an agent reactive with this peptide, a pharmaceutical composition... Agent: Mccarthy Tetrault LLP

20090246219 - Novel surface exposed haemophilus influenzae protein (protein e; pe): The present invention relates to a surface exposed protein (protein E; pE), a virulence factor, which can be detected in Haemophilus influenzae, having an amino acid sequence as described in SEQ ID NO 1, an immunogenic fragment of said surface exposed protein, and a recombinant immunogenic protein (pE (A)) or... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090246218 - S. aureus fibrinogen binding protein gene: The isolation of genes and proteins from Staphylococcus aureus is provided, and the nucleic acids coding for specific regions of the S. aureus protein are described. The nucleic acids encode proteins that can be useful as vaccines or in pharmaceutical compositions for application to prevent infection, promotion of wound healing,... Agent: Stites & Harbison Pllc

20090246220 - Constructs for enhancing immune responses: Chimeric protein constructs including a herpesvirus glycoprotein D (gD) and a heterologous polypeptide that interact with herpes virus entry mediator (HVEM) and enhance and enhance an immune response against the heterologous polypeptide and methods for their use are provided.... Agent: Banner & Witcoff, Ltd.

20090246221 - Immunomodulatory agents and methods of use: An antisense oligonucleotide compound, composition, vaccine and methods for treating a variety of conditions characterized by up-regulation of IL-10 in a mammalian subject are disclosed. The compound (i) is composed of morpholino subunits and phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5′ exocyclic carbon of... Agent: King & Spalding LLP

20090246222 - Live attenuated bordetella strains as a single dose vaccine against whooping cough: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of... Agent: Birch Stewart Kolasch & Birch

20090246223 - Inactivated chimeric vaccines and related methods of use: Embodiments of the present invention generally provide an inactivated chimeric virus vaccine and/or immunogenic composition for the treatment or prevention of viral infection. Further, various other embodiments of the present invention generally relate to methods of preventing and treating virus infection in such animals with the inactivated vaccine and/or immunogenic... Agent: Intervet/schering-plough Animal Health

20090246224 - Vaccine: The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090246225 - Methods of producing influenza vaccine compositions: Methods and compositions for the optimization of production of influenza viruses suitable as influenza vaccines are provided.... Agent: Medimmune, Llc Jonathan Klein-evans

20090246226 - Avian vaccines possessing a positive marker gene: The present invention provides a poultry vaccine containing a positive marker gene. More specifically, recombinant turkey herpesvirus modified by the presence of an extraneous antigen gene that may be used as a positive marker to identify and track vaccinated animals is provided. When inoculated into host animals, a poultry vaccine... Agent: Kratz, Quintos & Hanson, LLP

20090246227 - Methods of use for hsv-1 and hsv-2 vaccines: This invention provides methods of treating, suppressing, inhibiting, reducing an incidence, reducing the pathogenesis of, ameliorating the symptoms of, or ameliorating the secondary symptoms of a primary or recurring Herpes Simplex Virus (HSV) infection, or prolonging the latency to a relapse of an HSV infection, and disorders and symptoms associated... Agent: Pearl Cohen Zedek Latzer, LLP

20090246228 - Moraxella catarrhalis proteins: Novel antigens of B. catarrhalis are provided, together with their use in vaccines as well as methods of diagnosing and/or detection.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090246229 - Subunit vaccine of pasteurella multocida in veterinary uses: The present invention declaims the use of Pasteurella lipoprotein E (PlpE) as a subunit vaccine and the use of vaccines containing PlpE to protect animals from diseases caused by P. multocida. The results of vaccination and challenge experiments showed that mice and chickens immunized with PlpE were completely protected animals... Agent: Pai Patent & Trademark Law Firm

20090246230 - Compositions and methods for inducing tumor resistance: The invention provides a combined whole cell tumor vaccine for inducing tumor resistance in patients and treating cancer.... Agent: Foley And Lardner LLP Suite 500

20090246231 - Formulations containing borojo: The present invention relates to a cosmetic and skin care formulation comprising: borojo; and at least one humectant; and at least one emollient. The present invention also provides for a dietary and nutritional supplement comprising: borojo; at least one mineral; at least one vitamin and at least one protein.... Agent: Dan M. Delarosa

20090246232 - Pharmaceutical composition: Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.... Agent: Foley And Lardner LLP Suite 500

20090246233 - Treatment of gastroparesis and nonulcer dyspepsia with gabab agonists: The present invention relates to formulations comprising a therapeutically effective amount of baclofen or (R)-baclofen, or pharmaceutically acceptable salts thereof, and methods of their use. The present formulations and methods are designed to release a therapeutic amount of baclofen in a manner that maximizes its therapeutic effect. The methods and... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090246234 - therapeutic treatment using niacin for skin disorders: Niacin and/or niacinamides are incorporated with liposomes in therapeutic compositions for topical application to prevent or alleviate the conditions and symptoms of skin aging and other histological disorders. In particular, niacin and/or niacinamides are combined with liposomes to increase the penetration of the niacin and/or niacinamides into the deep epidermis... Agent: Glenn L. Webb Glenn L. Webb P.c.

20090246237 - Fluid powder dentifrice for the treatment of the gums, and a corresponding production method: a

20090246236 - Hair care compositions comprising sucrose polyesters: A hair care composition having a conditioning active comprising a sucrose polyester having a melting point greater than about 30° C., an IBAR greater than about 5, an IV of about 3 to about 70, and an aqueous carrier, and may further comprise optional ingredients including but not limited to,... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090246235 - Polyamide porous spherical particle: Polyamide porous spherical particles having a number-average particle diameter of 2 to 30 μm, a BET specific surface area of 100 to 80,000 m2/kg, and a ratio of a volume-average particle diameter to the number-average particle diameter in the range of 1.52 to 2.50 is reduced in luminous reflectance.... Agent: Nixon Peabody, LLP

20090246238 - Reinforced absorbable multilayered hemostatic wound dressing: The present invention is directed to a reinforced absorbable multilayered hemostatic wound dressing comprising a first absorbable nonwoven fabric, a second absorbable woven or knitted fabric, thrombin and/or fibrinogen.... Agent: Philip S. Johnson Johnson & Johnson

20090246239 - Insect growth regulating composition: A microencapsulated insect growth regulating composition comprising an insect growth regulation active ingredient in a wall formed of polyurethane or polyurea, having an average particle diameter of 1 to 40 μm, a wall thickness of 0.005 to 0.5 μm, a ratio of a wall thickness/an average particle diameter of 0.0003... Agent: Sughrue Mion, Pllc

20090246240 - Dry bactericidal nonwoven wipe: A dry bactericidal wipe that provides a greater than 99% reduction in bacterium including methicillin resistant Staphylococcus aureus (MRSA), Staphylococcus aureus, and Klebsiella pneumoniae. The dry bactericidal wipe comprises a nonwoven formed primarily of hydrophilic fibers and a binder distributed throughout the hydrophilic fibers in an amount effective to maintain... Agent: Womble Carlyle Sandridge & Rice, Pllc

20090246241 - Animal pest repellant device: An article of manufacture, comprising: an animal repellant dispersed over an artificial plant structure. The artificial plant structure may be a whole artificial plant or an artificial plant portion. The invention is also an article of manufacture comprising a band, wherein the band has an animal repellant or insect repellent... Agent: Gearhart Law, Llc

20090246242 - Method and device for protecting tobacco: A method for protecting tobacco from, during, comprises the step of covering the tobacco with a material, preferably a net, which has a protective activity against the harmful organisms.... Agent: Connolly Bove Lodge & Hutz, LLP

20090246243 - Carbonaceous protective multifunctional coatings: The present invention relates to Diamond-like Carbon (DLC) coatings on metal substrates and methods of making the same. The invention particularly relates, in a preferred embodiment, to a metallic substrate such as stainless steel or Ti alloy having a silicon material (such as an organosilicone, silicon nitride, silicon carbide or... Agent: Medtronic, Inc.

20090246248 - Coating compositions having improved performance: The presently disclosed subject matter provides compositions comprising a first substrate-binding domain (a peptide or a polymer) having binding affinity for a tissue or a medical device, a second substrate-binding domain having binding affinity for a target molecule, and the target molecule. In some embodiments, the first and second substrate-binding... Agent: Laura L.kiefer Affinergy, Inc.

20090246249 - Coating compositions having improved performance: The presently disclosed subject matter provides compositions comprising a first substrate-binding domain (a peptide or a polymer) having binding affinity for a tissue or a medical device, a second substrate-binding domain having binding affinity for a target molecule, and the target molecule. In some embodiments, the first and second substrate-binding... Agent: Laura L.kiefer Affinergy, Inc.

20090246250 - Coating compositions having improved performance: The presently disclosed subject matter provides compositions comprising a first substrate-binding domain (a peptide or a polymer) having binding affinity for a tissue or a medical device, a second substrate-binding domain having binding affinity for a target molecule, and the target molecule. In some embodiments, the first and second substrate-binding... Agent: Laura L.kiefer Affinergy, Inc.

20090246251 - Coating compositions having improved performance: The presently disclosed subject matter provides compositions comprising a first substrate-binding domain (a peptide or a polymer) having binding affinity for a tissue or a medical device, a second substrate-binding domain having binding affinity for a target molecule, and the target molecule. In some embodiments, the first and second substrate-binding... Agent: Laura L.kiefer Affinergy, Inc.

20090246247 - Composite enterocystoplasty: The present invention relates to methods for tissue augmentation or regeneration. More specifically, the present invention provides for a composite enterocystoplasty procedure using a biocompatible scaffold and minced autologous tissue for implantation in a mammalian bladder.... Agent: Philip S. Johnson Johnson & Johnson

20090246244 - Malleable multi-component implants and materials therefor: Described are implantable, malleable medical materials comprising mineral particles, insoluble collagen fibers, and a gel-forming polysaccharide component and/or another added gel-former. The malleable medical materials can be used treat bone or other tissue defects in patients, including in conjunction with biologically active factors such as osteogenic proteins. Also described are... Agent: Medtronic Attn: Noreen Johnson - Ip Legal Department

20090246246 - Processes for relieving blocked vessels and products thereby: Select microbials, microbiologicals, biologics and related naturally occurring or engineered microbial solutions supplement existing device modalities. Likewise, librarying and mapping processes are disclosed by which novel enhanced processes for relieving blocked vessels can be discovered, generated or improved for intravascular usages.... Agent: Luce, Forward, Hamilton & Scripps LLP

20090246245 - Subcutaneous implants releasing an active principle over an extended period of time: Subcutaneous implants obtained by extrusion containing an active ingredient, and a hydrophilic excipient dispersed in a PLGA matrix so that the weight ratio: (Active Ingredient (AI)+Excipient (E))/PLGA is higher than 0.05 and lower than 1.... Agent: Abelmen Frayne&schab

20090246252 - Insertable medical devices having microparticulate-associated elastic substrates and methods for drug delivery: The present invention provides insertable medical devices having elastic surfaces associated with bioactive agent-containing microparticulates and a coating material. Upon expansion of the elastic surfaces the microparticulates can be released to a subject.... Agent: Kagan Binder, Pllc

20090246253 - Methods of providing antioxidants to implantable medical devices: Methods of incorporating an antioxidant into a medical device including a polymer are described, and methods of packaging medical devices.... Agent: Squire, Sanders & Dempsey LLP

20090246254 - Non-hormonal vaginal contraceptive: The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the... Agent: Stroock & Stroock & Lavan LLP

20090246255 - Pharmaceutical compositions for the treatment of inner ear disorders: The present invention provides compositions containing (i) a pharmaceutically active agent selected from a group consisting of an arylcycloalkyamine or a derivative, analogue or pharmaceutically active salt thereof, and (ii) a biocompatible polymer or a combination of biocompatible polymers. These compositions or medicaments containing these compositions may be used for... Agent: Kevin Farrell Pierce Atwood

20090246256 - Compositions and methods for transmucosal delivery of lofexidine: The present invention provides for compositions and methods for accelerating the rate of delivery of lofexidine to the systemic circulation by transmucosal administration through the nasal, sublingual, or buccal routes to provide rapid response in the treatment of opiate addicts, migraine, neuropathic pain, and other therapeutic indications related to lofexidine,... Agent: Frost Brown Todd, Llc

20090246257 - Wafer formulation: An orally administrable wafer is provided comprising at least one physiologically acceptable film forming agent. The wafer is formed by mixing the film-forming agent with an aqueous solution to form a gel and exposing the gel to a plurality of heating and cooling cycles. The wafer is rapidly dissolving and... Agent: Valentine A Cottrill Susan Tandan

20090246258 - Antimicrobial and odor adsorbing textile: where R is a non-hyperbranched hydrocarbon group and the hydrocarbon group has at least one linear portion. The linear portion has between 5 and 30 carbon atoms, x is a number from 1 to 10,000, h-PEI is a hyperbranched polyethyleneimine, A is an organic compound having from 1 to 4... Agent: Legal Department (m-495)

20090246259 - Biocompatible material having biocompatible non-woven nano- or micro-fiber fabric produced by electrospinning method, and method for production of the material: e

20090246262 - Easily applied field dressing for wounds: A method for treating wounds by adhering a wound dressing to a wound with a polymerizable alkyl cyanoacrylate composition, such that the wound dressing and cyanoacrylate composition seal the wound to inhibit bleeding and infection. The dressing may be in the form of a mitten. Also disclosed is injection of... Agent: Knobbe Martens Olson & Bear LLP

20090246260 - Fibrin foam and process: A fibrin wound dressing is made by mixing quantities of fibrinogen solution and thrombin solution with air. The resulting foam is very light weight, and with the proper attention to the amount of thrombin, is also sufficiently viscous to rest on a vertical surface without dripping. The wound dressing may... Agent: K&l Gates LLP

20090246261 - Fibrin foam and process for making: A fibrin wound dressing is made by mixing quantities of fibrinogen solution and thrombin solution with air. The resulting foam is very light weight, and with the proper attention to the amount of thrombin, will rest on a vertical surface without dripping. The wound dressing may also be formulated for... Agent: K&l Gates LLP

20090246263 - Adhesive preparation: A patch preparation having a backing layer and a drug layer laminated on the backing layer; wherein the drug layer contains an adhesive containing at least one compound selected from the group consisting of fentanyl and pharmaceutically acceptable salts thereof, polyisobutylene, and a silicon-containing polymer; and a mass ratio of... Agent: The Nath Law Group

20090246265 - Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists: Described herein are compositions comprising opioids, opioid antagonists and prodrugs of the same, formulations comprising opioids, opioid antagonists and prodrugs of the same, and methods of using opioids, opioid antagonists and prodrugs of the same. One embodiment described herein relates to the transdermal administration of a buprenorphine and encapsulated naltrexone... Agent: Mayer Brown LLP

20090246266 - Preparation and composition of meloxicam transdermal drug delivery system: A composition for transdermal permeation and a preparation method are disclosed. The composition including meloxicam as an active ingredient and further including at least one permeation enhancing agent selected from the group consisting of a sorbitan fatty acid derivative, a polyglyceryl fatty acid derivative, a polyethylene glycol vegetable oil ester,... Agent: Lucas & Mercanti, LLP

20090246264 - Transdermal tobacco alkaloid patch: c

20090246267 - Carnitine conjugates of adamantanamines and neramexane derivatives as dual prodrugs for various uses: This invention concerns compounds of adamantanamines and neramexane, including their pharmaceutically-acceptable salts, diesterioisomers, and formulations for treating Alzheimer's related dementias, depression, AIDS related dementias, as antivirals, inflammatory diseases such as rheumatoid arthritis, and cerebral ischemia, hyperlipidemia, and diabetes.... Agent: Technology Law, Pllc

20090246271 - Combination of ceramide and gemcitabine for inducing cell death and uses thereof in treating cancer: This invention provides a method for increasing apoptosis in a cancer cell comprising contacting the cancer cell with (a) gemcitabine and (b) C6-ceramide, sequentially or concomitantly, wherein the gemcitabine and C6-ceramide are in amounts such that the apoptosis induced by the combination of gemcitabine and C6-ceramide is greater than the... Agent: Cooper & Dunham, LLP

20090246269 - Identification and use of gprc variants in the treatment and diagnosis of parkinson's disease: The invention relates genes that are deregulated in Parkinson's disease tissues and the corresponding proteins are identified. These genes and the corresponding proteins are suitable targets for the treatment of Parkinson's disease. Also, the invention relates to compounds and their uses, particularly in the pharmaceutical industry. The invention more specifically... Agent: Nixon & Vanderhye, Pc

20090246273 - Ketorolac sublingual spray for the treatment of pain: The present invention provides for compositions and methods for accelerating the rate of delivery of ketorolac to the systemic circulation by sublingual spray administration under the tongue to provide a rapid response in the treatment of pain, especially acute pain associated with postoperative pain and migraine headache. Compositions of ketorolac... Agent: Frost Brown Todd, Llc

20090246268 - Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors: A method for preparing a stable dispersion of a camptothecin, camptothecin prodrug, or analog thereof for administration to a patient in need thereof includes preparing a solution of the camptothecin, wherein the solution has a pH which places substantially an entirety of that camptothecin in a carboxylate form. The camptothecin... Agent: King & Schickli, Pllc

20090246272 - Mda-7 proteins and methods of use thereof: This invention provides a method of generating a subtracted cDNA library of a cell comprising: a) generating a cDNA library of the cell; b) isolating double-stranded DNAs from the cDNA library; c) releasing the double-stranded cDNA inserts from the double-stranded DNAs; d) denaturing the isolated double-stranded cDNA inserts; e) hybridizing... Agent: Baker Botts L.l.p.

20090246270 - Use of iontophoresis or electrotherapy and ultrasound to deliver agents for skin rejuvenation.: The method disclosed includes the combining of iontophoresis or electrotherapy and ultrasound to deliver the appropriate chromophores to the skin for cosmetic or therapeutic treatment of the skin and skin conditions by the use of a laser, Intense Pulsed Light (IPL), a combination of laser and Radio Frequency (RF) energy,... Agent: Dennis R. Jones Ste:112

20090246274 - Pharmaceutical composition 271: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.... Agent: Hogan & Hartson LLP

20090246275 - Compositions and methods for delivery of embolics: Described herein are compositions comprising one or more embolics attached to an inert, dissolvable matrix as well as kits comprising these novel embolic formulations. Also described are methods of making and using these embolic formulations.... Agent: Robins & Pasternak

20090246276 - Pharmaceutical compositions: The present invention relates to a pharmaceutical composition comprising a tablet core comprising a combination of actives selected from the group consisting of bupropion hydrochloride and escitalopram oxalate, bupropion hydrobromide and citalopram hydrochloride, bupropion hydrobromide and escitalopram oxalate, and bupropion hydrobromide and quetiapine fumarate, and at least one pharmaceutically acceptable... Agent: Lovells LLP

20090246277 - Controlled release system: The invention relates to a system for controlled release of medicinally active substances, which comprises sucrose acetate isobutyrate (SAIB) and a further solvent.... Agent: Bayer Healthcare Llc

20090246278 - Use of essential oils to reduce benzodiazepine requirements during medical procedures: A method to reduce or eliminate the need for medicaments such as benzodiazepine and narcotics in noxious medical procedures, such as intravenous needle insertion, mechanical ventilation and intubation procedures, includes topically administering to the patient an effective amount of an essential oil composition including at least one essential oil selected... Agent: Amin Talati, Llc

20090246279 - Particles having hydrophobic material therein: A process for preparing particles having a hydrophobic material therein is disclosed. The process comprises providing a multiple emulsion comprising a first emulsion dispersed in a hydrophobic medium, said first emulsion comprising a hydrophobic phase dispersed in a hydrophilic phase, wherein the hydrophobic phase comprises the hydrophobic material and the... Agent: Foley And Lardner LLP Suite 500

20090246280 - Resin powder containing aluminum salt, process for production of the same, and resin composition, phosphorus adsorbent, antibacterial agent or antifungal agent comprising the same: An aluminum salt-containing resin powder of the present invention includes: at lest one matrix resin component selected from regenerated collagen, polyvinyl alcohol and carboxymethyl cellulose; and an aluminum salt. The aluminum salt is chemically bonded to the matrix resin component, and the resultant is powdered. A resin composition of the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090246284 - O-desmethylvenlafaxine cocrystals: Disclosed herein are co-crystals comprising O-desmethylvenlafaxine and succinic acid, process for the preparation, pharmaceutical compositions, and method of treating thereof.... Agent: Cantor Colburn LLP

20090246282 - Recombinant gelatin particles for cell adhesion: The present invention relates to cell carrier particles prepared from recombinantly produced gelatins comprising at least two outer lysine residues which are separated by at least 25 percent of the total number of amino acids in the recombinant gelatin polypeptide. The invention is also directed at applications in which such... Agent: Foley And Lardner LLP Suite 500

20090246283 - Repeat sequence protein polymer nanoparticles optionally containing active agents and their preparation: A nanocomposite of a repeat sequence protein polymer, such as a copolymer of silk and elastin, is produced by Supercritical Antisolvent Precipitation with Enhanced Mass Transfer (SAS-EM). The nanocomposite may include an active agent, such as a protein or hormone, that is releasably bound to the repeat sequence protein polymer.... Agent: Jill A. Jacobson Genencor International

20090246281 - Soft steroid compositions for use in dry powder inhalers: A medicament and a method of producing a medicament are disclosed. The medicament contains a soft steroid and is suitable for administration via a dry powder inhaler.... Agent: Kenyon & Kenyon LLP

20090246285 - Monodispersed organic monolayer coated calcium-containing nanoparticles: A method for the synthesis of monodispersed, organic-monolayer coated, calcium-containing nanoparticles is presented. A biphasic liquid system comprises an aqueous phase of bare particles and an organic phase containing organic molecules with carboxylic acid end group is mixed. The carboxylic acid group binds to the surface of the calcium-containing particles... Agent: Pearl Cohen Zedek Latzer, LLP

20090246286 - Particle for medical use and process for producing the same: The present invention has solved the above problem with a particle for medical use having a layer containing a polymer compound formed on a surface of a core particle, wherein the polymer compound is a polymer comprising at least repeating units derived from an ethylenically unsaturated polymerizable monomer (a) having... Agent: Smith, Gambrell & Russell

20090246287 - Anti-allergy compositions: The present invention relates to particles of glucans, particularly oxidized cellulosed for use in medicine. The invention further discloses pharmaceutical compositions for the treatment and/or prophylaxis of diseases or disorders associated with or mediated by allergens.... Agent: Brooks Kushman P.c.

20090246288 - Taste-masking oral dosage form and method of preparing the same: The present invention provides a taste-masking oral dosage form which comprises a taste-masked microparticle and an excipient. The taste-masked microparticle comprises a taste-masked crystal containing an active pharmaceutical ingredient masked by a hydrophilic polymer and a starch. The present invention also provides a method for making the taste-masked microparticles and... Agent: Andrews Kurth LLP

20090246289 - System and method for diagnosing and managing those at risk for cardiovascular disease: A system and method for diagnosing and managing patients at risk for cardiovascular disease. The system and method provides for automating the ordering of a number of advanced tests, compiling and evaluating test results, and producing an automated report which includes recommended disease management options.... Agent: Snell & Wilmer L.l.p. (main)

20090246290 - Lipid metabolism improving agent containing hydrogen molecules: The lipid metabolism improving agent of the present invention comprises a liquid or gas containing at least hydrogen molecules. It may comprise a medium containing oxygen molecules. Further, such medium may comprise water, an aqueous solution, or a gas. The lipid metabolism improving agent has effects of suppressing body fat... Agent: Wenderoth, Lind & Ponack, L.l.p.

20090246291 - Method and compositions for treatment of cancer: The present invention relates to a method of treating cancer in a subject in need thereof, by administering to the subject a combination of sodium meta arsenite and/or arsenic trioxide and a cytotoxic anticancer agent, such as cisplatin, adriamycin, and taxane, such as larotaxel, orataxel, tesetaxel, docetaxel or paclitaxel. The... Agent: Mcdermott Will & Emery LLP

20090246292 - Antimicrobial formulations comprising a quinone and a copper salt: An antimicrobial formulation containing a quinone, such as a benzoquinone or hydroquinone, and a copper salt. The formulation may in particular be used against staphylococci or propionibacteria, more particularly to treat skin and skin structure conditions such as acne.... Agent: Weaver Austin Villeneuve & Sampson LLP

20090246293 - Compositions and methods to control oomycete fungal pathogens: The present invention relates to compounds and the use of such compounds for increasing the efficacy of fungicides for controlling oomycete pathogen induced disease or diseases in one or more plants.... Agent: Dow Agrosciences Llc

20090246294 - Pigment mixture, and use thereof in cosmetics, food and pharmaceuticals: The invention relates to pigment mixtures comprising at least two components A and B. The inventive pigment mixtures are characterized in that component A is embodied as effect pigments while component B is embodied as coloring agents and fillers. Also disclosed is the use of said pigment mixtures in cosmetic... Agent: Millen, White, Zelano & Branigan, P.c.

20090246295 - Preparation of concentrated aqueous bromine solutions and biocidal applications thereof: A process of producing a concentrated liquid biocide formulation is described. Mixed together are (a) bromine and (b) an aqueous solution of alkali metal salt of sulfamic acid having a pH of at least about 12, in amounts such that (i) the active bromine content of the solution is at... Agent: Albemarle Corporation

20090246296 - Method of treating ischemia/reperfusion injury with nitroxyl donors: Nitroxyl donating compounds are administered prior to the onset of ischemia for the prevention and/or reduction of ischemia/reperfusion injury in subjects at risk for ischemia. Nitroxyl donors also are administered to organs to be transplanted for the prevention and/or reduction of ischemia/reperfusion injury upon reperfusion in a recipient. Nitroxyl donors... Agent: Morrison & Foerster LLP

20090246297 - Turf mold remediation: A method for treating diseased plants, such as turf and trees, includes mixing a quantity of a plant remediation composition with water and applying the plant remediation composition to the diseased plants. The plant remediation composition may include from about 30 to about 50 volume percent of a potassium silicate,... Agent: Holland & Knight LLP

20090246299 - Fat composition: m

20090246298 - Viagra: 3. Skull Cap works on the body using the volatile fixed oils, (essential oil) The main color titrated out is green, green works on the heart. In the Contraction phase the heart rests. There are seven botanical herbs in the Magistral Viagra. The synergistic effect causes the free flow of... Agent: Ceola P. Steele

20090246300 - Adaptogenic tea: A natural adaptogenic tea is prepared from adaptogens to counter adverse physical, chemical, or biological stressors and to promote t-cell activity and k-cell activity. Also, the composition is high in antioxidants and discourages free radicals. Moreover, the composition improves liver performance, resulting in improved toxin removal and improved nutrient absorption.... Agent: Delaney Ip

20090246301 - Method for treating irritable bowel syndrome and other functional gastrointestinal disorders: The invention relates to methods and compositions for the treatment of irritable bowel syndrome (IBS) and other functional gastrointestinal disorders. The methods of the invention involve the administration, in a delayed-release capsule or tablet containing a mixture of peppermint oil and chlorophyll. Other ingredients that may also be effective treatments... Agent: Jonathan D. Feuchtwang

20090246302 - Composition and method for protecting agricultural crops and/or agricultural products: The present invention provides a composition and a method for protecting agricultural crops and/or agricultural products against insects/pests. The said composition comprising an effective amount of extract obtained from Piper betle Linn. The plant material prepared in accordance with this invention is extremely effective in reducing insect populations and preventing... Agent: Edwards Angell Palmer & Dodge LLP

20090246303 - Method for reducing the effects of chemotherapy using flagellin related polypeptides: The use of flagellin and flagellin related polypeptides for reducing cancer treatment side effects in mammals is described.... Agent: Polsinelli Shughart Pc